These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24982330)

  • 1. Advantage of lutetium-177 versus radioiodine immunoconjugate in targeted radionuclide therapy of b-cell tumors.
    Repetto-Llamazares A; Abbas N; Bruland ØS; Dahle J; Larsen RH
    Anticancer Res; 2014 Jul; 34(7):3263-9. PubMed ID: 24982330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 177Lu-DOTA-HH1, a novel anti-CD37 radio-immunoconjugate: a study of toxicity in nude mice.
    Repetto-Llamazares AH; Larsen RH; Giusti AM; Riccardi E; Bruland ØS; Selbo PK; Dahle J
    PLoS One; 2014; 9(7):e103070. PubMed ID: 25068508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma.
    Repetto-Llamazares AH; Larsen RH; Patzke S; Fleten KG; Didierlaurent D; Pichard A; Pouget JP; Dahle J
    PLoS One; 2015; 10(6):e0128816. PubMed ID: 26066655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma.
    Postema EJ; Frielink C; Oyen WJ; Raemaekers JM; Goldenberg DM; Corstens FH; Boerman OC
    Cancer Biother Radiopharm; 2003 Aug; 18(4):525-33. PubMed ID: 14503946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49.
    Chauhan SC; Jain M; Moore ED; Wittel UA; Li J; Gwilt PR; Colcher D; Batra SK
    Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):264-73. PubMed ID: 15791435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
    Tolmachev V; Orlova A; Pehrson R; Galli J; Baastrup B; Andersson K; Sandström M; Rosik D; Carlsson J; Lundqvist H; Wennborg A; Nilsson FY
    Cancer Res; 2007 Mar; 67(6):2773-82. PubMed ID: 17363599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
    Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
    J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
    Stein R; Govindan SV; Chen S; Reed L; Richel H; Griffiths GL; Hansen HJ; Goldenberg DM
    J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.
    Frost SH; Frayo SL; Miller BW; Orozco JJ; Booth GC; Hylarides MD; Lin Y; Green DJ; Gopal AK; Pagel JM; Bäck TA; Fisher DR; Press OW
    PLoS One; 2015; 10(3):e0120561. PubMed ID: 25785845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical evaluation of a diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model.
    Weber T; Bötticher B; Arndt MA; Mier W; Sauter M; Exner E; Keller A; Krämer S; Leotta K; Wischnjow A; Grosse-Hovest L; Strumberg D; Jäger D; Gröne HJ; Haberkorn U; Brem G; Krauss J
    Cancer Lett; 2016 Oct; 381(2):296-304. PubMed ID: 27524505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide-labeled immunoconjugates.
    Schott ME; Schlom J; Siler K; Milenic DE; Eggensperger D; Colcher D; Cheng R; Kruper WJ; Fordyce W; Goeckeler W
    Cancer; 1994 Feb; 73(3 Suppl):993-8. PubMed ID: 8306291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2×Anti-HSG Bispecific Antibody and a (177)Lu-Labeled Peptide.
    van Rij CM; Frielink C; Goldenberg DM; Sharkey RM; Lütje S; McBride WJ; Oyen WJ; Boerman OC
    Cancer Biother Radiopharm; 2014 Oct; 29(8):323-9. PubMed ID: 25226447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications.
    Milenic DE; Garmestani K; Chappell LL; Dadachova E; Yordanov A; Ma D; Schlom J; Brechbiel MW
    Nucl Med Biol; 2002 May; 29(4):431-42. PubMed ID: 12031878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetraspanin 8 (TSPAN 8) as a potential target for radio-immunotherapy of colorectal cancer.
    Maisonial-Besset A; Witkowski T; Navarro-Teulon I; Berthier-Vergnes O; Fois G; Zhu Y; Besse S; Bawa O; Briat A; Quintana M; Pichard A; Bonnet M; Rubinstein E; Pouget JP; Opolon P; Maigne L; Miot-Noirault E; Chezal JM; Boucheix C; Degoul F
    Oncotarget; 2017 Mar; 8(13):22034-22047. PubMed ID: 28423546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas.
    Pagel JM; Pantelias A; Hedin N; Wilbur S; Saganic L; Lin Y; Axworthy D; Hamlin DK; Wilbur DS; Gopal AK; Press OW
    Cancer Res; 2007 Jun; 67(12):5921-8. PubMed ID: 17575162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biodistribution and radioimmunotherapy of SCCHN in xenotransplantated SCID mice with a 131I-labelled anti-EpCAM monoclonal antibody.
    Andratschke M; Gildehaus FJ; Johannson V; Schmitt B; Mack B; Reisbach G; Lang S; Lindhofer H; Zeidler R; Wollenberg B; Luebbers CW
    Anticancer Res; 2007; 27(1A):431-6. PubMed ID: 17352264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22.
    Sharkey RM; Behr TM; Mattes MJ; Stein R; Griffiths GL; Shih LB; Hansen HJ; Blumenthal RD; Dunn RM; Juweid ME; Goldenberg DM
    Cancer Immunol Immunother; 1997 May; 44(3):179-88. PubMed ID: 9191878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcinoembryonic antigen monoclonal antibody.
    Stein R; Govindan SV; Hayes M; Griffiths GL; Hansen HJ; Horak ID; Goldenberg DM
    Clin Cancer Res; 2005 Apr; 11(7):2727-34. PubMed ID: 15814655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of 177Lu-DOTA-labeled aglycosylated monoclonal anti-L1-CAM antibody chCE7: influence of the number of chelators on the in vitro and in vivo properties.
    Knogler K; Grünberg J; Novak-Hofer I; Zimmermann K; Schubiger PA
    Nucl Med Biol; 2006 Oct; 33(7):883-9. PubMed ID: 17045168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.